Your browser doesn't support javascript.
loading
Biomarkers in clinical drug development.
Gobburu, J V S.
Affiliation
  • Gobburu JV; Division of Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. jogarao.gobburu@fda.hhs.gov
Clin Pharmacol Ther ; 86(1): 26-7, 2009 Jul.
Article in En | MEDLINE | ID: mdl-19536121
The primary purpose of this Commentary is to complement the description of biomarkers given in this issue in the Pharmaceutical Research and Manufacturers of America report by Lathia et al. I offer several examples of the use of biomarkers that highlight their value in drug development and regulatory decision making.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Drug Discovery Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Clin Pharmacol Ther Year: 2009 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Drug Discovery Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Clin Pharmacol Ther Year: 2009 Document type: Article Affiliation country: United States Country of publication: United States